Hao Yue, Wang Qian, Wang Ke, Chen Chengyu, Xu Chunwei, Wang Dong, Song Yong, Song Zhengbo, Lv Tangfeng
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Department of Respiratory Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu, China.
Ther Adv Med Oncol. 2025 May 30;17:17588359251338397. doi: 10.1177/17588359251338397. eCollection 2025.
Non-small-cell lung cancer (NSCLC) with human epidermal growth factor receptor 2 (HER2) mutations poses significant treatment challenges. While chemotherapy combined with immunotherapy or anti-angiogenic therapy has been explored, no standardized regimen exists for these patients. This study aims to evaluate the efficacy of different treatment regimens for HER2-mutated NSCLC.
Our study aimed to investigate the survival among NSCLC patients with HER2 mutation who received various treatment regimens in real-world settings, providing insights and guidance for clinical practice.
Survival analyses were conducted on patients who underwent different treatment regimens, including chemotherapy, immunotherapy, tyrosine kinase inhibitors (TKIs), and combination therapies, to evaluate their effectiveness.
This retrospective study included 118 patients diagnosed with HER2 mutations through next-generation sequencing at Zhejiang Cancer Hospital and Jinling Hospital affiliated with Nanjing University Medical School from September 2017 to December 2024. Data on treatment regimens and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS), were collected. Kaplan-Meier analysis estimated PFS and OS, and Cox regression identified factors influencing PFS.
Among the 118 patients, ORR and DCR were 22.9% and 58.5%, respectively. Median PFS and OS were 7.3 and 44.9 months, respectively. Combination therapies significantly improved PFS compared to single chemotherapy or immunotherapy or TKIs group (7.8 vs 5.3 months, = 0.001). Patients with brain metastases also showed better PFS with combination therapies (7.8 vs 2.8 months, = 0.001). The chemotherapy, immunotherapy, and anti-angiogenic therapy combination (C + I + A) yielded the best outcomes, with a PFS of 16.3 months. Cox regression revealed treatment regimen as the only factor significantly influencing PFS.
Combination regimens, especially C + I + A, significantly improve PFS and offer superior therapeutic benefits for patients with HER2-mutated NSCLC compared to single chemotherapy or immunotherapy or TKIs treatments.
携带人表皮生长因子受体2（HER2）突变的非小细胞肺癌（NSCLC）带来了重大的治疗挑战。虽然已经探索了化疗联合免疫疗法或抗血管生成疗法，但这些患者尚无标准化治疗方案。本研究旨在评估HER2突变型NSCLC不同治疗方案的疗效。
我们的研究旨在调查在现实世界中接受各种治疗方案的HER2突变型NSCLC患者的生存情况，为临床实践提供见解和指导。
对接受不同治疗方案（包括化疗、免疫疗法、酪氨酸激酶抑制剂（TKIs）和联合疗法）的患者进行生存分析，以评估其有效性。
这项回顾性研究纳入了2017年9月至2024年12月期间在浙江大学医学院附属肿瘤医院和南京大学医学院附属金陵医院通过二代测序诊断为HER2突变的118例患者。收集了治疗方案和临床结局的数据，包括客观缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）和总生存期（OS）。采用Kaplan-Meier分析估计PFS和OS，并通过Cox回归确定影响PFS的因素。
在118例患者中，ORR和DCR分别为22.9%和58.5%。中位PFS和OS分别为7.3个月和44.9个月。与单纯化疗、免疫疗法或TKIs组相比，联合疗法显著改善了PFS（7.8个月对5.3个月，P = 0.001）。有脑转移的患者接受联合疗法时也显示出更好的PFS（7.8个月对2.8个月，P = 0.001）。化疗、免疫疗法和抗血管生成疗法联合（C + I + A）产生了最佳结果，PFS为16.3个月。Cox回归显示治疗方案是显著影响PFS的唯一因素。
与单纯化疗、免疫疗法或TKIs治疗相比，联合方案，尤其是C + I + A，显著改善了HER2突变型NSCLC患者的PFS，并提供了更好的治疗益处。
